Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors: A review of the literature

Denise Soltow Hershey, Ashley Leak Bryant, Jill Olausson, Ellen D. Davis, Veronica J. Brady, Marilyn Hammer

Research output: Contribution to journalArticle

Abstract

Purpose/Objectives: To review the literature regarding the development of hyperglycemia associated with neoadjuvant agents used in the treatment of solid tumor cancers. Data Sources: Research articles were obtained from PubMed, CINAHL®, and Cochrane Reviews. The following search terms were used alone and in combination: diabetes, glycemic control, chemotherapy, androgen deprivation therapy, interferon-alpha, immunosuppressants, cancer, neoplasms, and hyperglycemia. Data Synthesis: Twenty-two studies were identified reporting the development of hyperglycemic events in patients who received a variety of chemotherapeutic agents. Conclusions: Findings suggest patients are at risk for the development of hyperglycemia from certain chemotherapeutic agents. Docetaxel, everolimus, and temsirolimus alone or in combination with other agents can promote hyperglycemia. Androgen-deprivation therapy commonly used in prostate cancer, increases the risk for the development of hyperglycemia and diabetes. Implications for Nursing: Oncology nurses play an important role in the identification and treatment of hyperglycemia in patients receiving chemotherapy. Future research is needed that focuses on the association between glycemic control and adverse outcomes in patients with a solid tumor cancer who are at risk for treatment-induced hyperglycemia.

Original languageEnglish (US)
Pages (from-to)E343-E354
JournalOncology Nursing Forum
Volume41
Issue number6
DOIs
StatePublished - Nov 1 2014

Fingerprint

Hyperglycemia
Neoplasms
docetaxel
Therapeutics
Androgens
Oncology Nursing
Drug Therapy
Information Storage and Retrieval
Immunosuppressive Agents
PubMed
Interferon-alpha
Prostatic Neoplasms
Nurses
Research

Keywords

  • Chemotherapy
  • Hyperglycemia
  • Neoplasm

ASJC Scopus subject areas

  • Oncology(nursing)
  • Medicine(all)

Cite this

Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors : A review of the literature. / Hershey, Denise Soltow; Bryant, Ashley Leak; Olausson, Jill; Davis, Ellen D.; Brady, Veronica J.; Hammer, Marilyn.

In: Oncology Nursing Forum, Vol. 41, No. 6, 01.11.2014, p. E343-E354.

Research output: Contribution to journalArticle

Hershey, Denise Soltow ; Bryant, Ashley Leak ; Olausson, Jill ; Davis, Ellen D. ; Brady, Veronica J. ; Hammer, Marilyn. / Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors : A review of the literature. In: Oncology Nursing Forum. 2014 ; Vol. 41, No. 6. pp. E343-E354.
@article{8984c231ee3f41849fc0c339da8853d3,
title = "Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors: A review of the literature",
abstract = "Purpose/Objectives: To review the literature regarding the development of hyperglycemia associated with neoadjuvant agents used in the treatment of solid tumor cancers. Data Sources: Research articles were obtained from PubMed, CINAHL{\circledR}, and Cochrane Reviews. The following search terms were used alone and in combination: diabetes, glycemic control, chemotherapy, androgen deprivation therapy, interferon-alpha, immunosuppressants, cancer, neoplasms, and hyperglycemia. Data Synthesis: Twenty-two studies were identified reporting the development of hyperglycemic events in patients who received a variety of chemotherapeutic agents. Conclusions: Findings suggest patients are at risk for the development of hyperglycemia from certain chemotherapeutic agents. Docetaxel, everolimus, and temsirolimus alone or in combination with other agents can promote hyperglycemia. Androgen-deprivation therapy commonly used in prostate cancer, increases the risk for the development of hyperglycemia and diabetes. Implications for Nursing: Oncology nurses play an important role in the identification and treatment of hyperglycemia in patients receiving chemotherapy. Future research is needed that focuses on the association between glycemic control and adverse outcomes in patients with a solid tumor cancer who are at risk for treatment-induced hyperglycemia.",
keywords = "Chemotherapy, Hyperglycemia, Neoplasm",
author = "Hershey, {Denise Soltow} and Bryant, {Ashley Leak} and Jill Olausson and Davis, {Ellen D.} and Brady, {Veronica J.} and Marilyn Hammer",
year = "2014",
month = "11",
day = "1",
doi = "10.1188/14.ONF.E343-E354",
language = "English (US)",
volume = "41",
pages = "E343--E354",
journal = "Oncology Nursing Forum",
issn = "0190-535X",
publisher = "Oncology Nursing Society",
number = "6",

}

TY - JOUR

T1 - Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors

T2 - A review of the literature

AU - Hershey, Denise Soltow

AU - Bryant, Ashley Leak

AU - Olausson, Jill

AU - Davis, Ellen D.

AU - Brady, Veronica J.

AU - Hammer, Marilyn

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Purpose/Objectives: To review the literature regarding the development of hyperglycemia associated with neoadjuvant agents used in the treatment of solid tumor cancers. Data Sources: Research articles were obtained from PubMed, CINAHL®, and Cochrane Reviews. The following search terms were used alone and in combination: diabetes, glycemic control, chemotherapy, androgen deprivation therapy, interferon-alpha, immunosuppressants, cancer, neoplasms, and hyperglycemia. Data Synthesis: Twenty-two studies were identified reporting the development of hyperglycemic events in patients who received a variety of chemotherapeutic agents. Conclusions: Findings suggest patients are at risk for the development of hyperglycemia from certain chemotherapeutic agents. Docetaxel, everolimus, and temsirolimus alone or in combination with other agents can promote hyperglycemia. Androgen-deprivation therapy commonly used in prostate cancer, increases the risk for the development of hyperglycemia and diabetes. Implications for Nursing: Oncology nurses play an important role in the identification and treatment of hyperglycemia in patients receiving chemotherapy. Future research is needed that focuses on the association between glycemic control and adverse outcomes in patients with a solid tumor cancer who are at risk for treatment-induced hyperglycemia.

AB - Purpose/Objectives: To review the literature regarding the development of hyperglycemia associated with neoadjuvant agents used in the treatment of solid tumor cancers. Data Sources: Research articles were obtained from PubMed, CINAHL®, and Cochrane Reviews. The following search terms were used alone and in combination: diabetes, glycemic control, chemotherapy, androgen deprivation therapy, interferon-alpha, immunosuppressants, cancer, neoplasms, and hyperglycemia. Data Synthesis: Twenty-two studies were identified reporting the development of hyperglycemic events in patients who received a variety of chemotherapeutic agents. Conclusions: Findings suggest patients are at risk for the development of hyperglycemia from certain chemotherapeutic agents. Docetaxel, everolimus, and temsirolimus alone or in combination with other agents can promote hyperglycemia. Androgen-deprivation therapy commonly used in prostate cancer, increases the risk for the development of hyperglycemia and diabetes. Implications for Nursing: Oncology nurses play an important role in the identification and treatment of hyperglycemia in patients receiving chemotherapy. Future research is needed that focuses on the association between glycemic control and adverse outcomes in patients with a solid tumor cancer who are at risk for treatment-induced hyperglycemia.

KW - Chemotherapy

KW - Hyperglycemia

KW - Neoplasm

UR - http://www.scopus.com/inward/record.url?scp=84911490333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911490333&partnerID=8YFLogxK

U2 - 10.1188/14.ONF.E343-E354

DO - 10.1188/14.ONF.E343-E354

M3 - Article

C2 - 25355030

AN - SCOPUS:84911490333

VL - 41

SP - E343-E354

JO - Oncology Nursing Forum

JF - Oncology Nursing Forum

SN - 0190-535X

IS - 6

ER -